TY  - JOUR
PY  - 2020//
TI  - Reduced serum VGF levels are linked with suicide risk in Chinese Han patients with major depressive disorder
JO  - BMC psychiatry
A1  - Li, Xingxing
A1  - Ge, Huifei
A1  - Zhou, Dongsheng
A1  - Wu, Xiangping
A1  - Qi, Gangqiao
A1  - Chen, Zan
A1  - Yu, Chang
A1  - Zhang, Yuanyuan
A1  - Yu, Haihang
A1  - Wang, Chuang
SP  - e225
EP  - e225
VL  - 20
IS  - 1
N2  - BACKGROUND: VGF (nonacronymic) is a neuropeptide that plays an important role in the pathogenesis of major depressive disorder (MDD). However, no studies have yet investigated VGF levels in patients with MDD who are at risk of suicide. The purpose of the present study was to determine whether serum VGF levels are related to suicide risk in patients with MMD. <br><br>METHODS: A total of 107 patients with MDD and 40 normal control participated in the present study. The risk of suicide was assessed using the Nurses Global Assessment of Suicide Risk (NGASR). On this basis, 60 patients were assigned to a high-risk group (NGASR≥9) and 47 were assigned to a low-risk group (NGASR< 9). The severity of depression was measured using the 17-item Hamilton Depression Rating Scale (HDRS). Levels of serum VGF were determined using a double antibody sandwich enzyme-linked immunosorbent assay. <br><br>RESULTS: Serum VGF levels in the high-risk group (883.34 ± 139.67 pg/mL) were significantly lower than in the low-risk group (1020.56 ± 131.76 pg/mL) and in the control group (1107.00 ± 155.38 pg/mL) (F = 31.90, p < 0.001). In patients with MDD, suicide risk was significantly negatively correlated with VGF levels (r = - 0.55, p = 0.001). <br><br>CONCLUSIONS: Reduced serum VGF levels are related to risk of suicide in patients with MDD, so VGF may be a biomarker of suicide risk in MDD.<p />  <p>Language: en</p>
LA  - en
SN  - 1471-244X
UR  - http://dx.doi.org/10.1186/s12888-020-02634-9
ID  - ref1
ER  -